The ACY1 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population derived from the A-549 human lung adenocarcinoma cell line, designed to disrupt the ACY1 gene encoding aminoacylase 1. This heterogeneous knockout stock comprises a mixture of cells with targeted ACY1 disruption, providing a robust loss-of-function model that avoids clonal selection artifacts. It serves as a key tool for investigating the role of ACY1 in amino acid metabolism and cancer biology.
The parental A-549 cell line is a hypotriploid human lung epithelial adenocarcinoma model harboring a KRAS G12S activating mutation. Isolated from a 58-year-old Caucasian male, it is widely used in non-small cell lung cancer research for studying oncogenic signaling, metabolic reprogramming, and drug responses. Its adherent, epithelial morphology and well-annotated genomic background make it an appropriate host for exploring metabolic gene function.
ACY1 encodes aminoacylase 1, a cytosolic enzyme that hydrolyzes N-acetylated amino acids into free amino acids??notably methionine and alanine??and acetate. These products are critical for mTORC1 pathway activation and for maintaining the acetyl-CoA pool, which influences protein acetylation. ACY1 expression is putatively regulated by the transcription factor SP1 and cellular metabolic status. In this knockout model, ablation of ACY1 activity leads to accumulation of N-acetylated amino acid substrates and depletion of free methionine, alanine, and acetate, thereby suppressing mTORC1 signaling (evidenced by reduced phosphorylation of S6K1 and 4EBP1) and altering global acetylation patterns.
Within the KRAS-driven A-549 adenocarcinoma context, ACY1 disruption illuminates the reliance of cancer cells on amino acid salvage pathways. Loss of ACY1-mediated recycling may impair amino acid homeostasis and mTORC1 activation, potentially exposing metabolic vulnerabilities. This model enables dissection of how ACY1 loss affects proliferation, acetylation dynamics, and sensitivity to metabolic perturbations, offering insights into lung adenocarcinoma biology.
Typical applications include validation of knockout efficiency by western blotting or RT-qPCR, and metabolomic profiling of N-acetylated amino acids via LC-MS. Functional assays assess proliferation, migration, and invasion. mTOR pathway activity is monitored through phospho-S6K1 and phospho-4EBP1 analysis, while acetylation alterations are detected by immunofluorescence or western blot. Further, the cells can be employed in drug sensitivity screens to identify compounds targeting metabolic weaknesses arising from ACY1 loss. For additional information, please reach out to Ascent Research.
